Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
Authors:
- 1 April 2024
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 10 (4) , 532-535
Abstract
This case-control study examines the incidence and risks of myeloid neoplasms in adults treated for B-cell lymphoproliferative disorders or multiple myeloma.Keywords
This publication has 5 references indexed in Scilit:
- Long-term outcomes following CAR T cell therapy: what we know so farNature Reviews Clinical Oncology, 2023
- Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin LymphomaBlood Cancer Journal, 2022
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell LymphomaBlood Cancer Discovery, 2022
- CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphomaBlood, 2021